SEC Form 4 · accession 0001104659-16-108203

Corvus Pharmaceuticals, Inc. · CRVS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Mar 29, 2016

Accepted (ET)

Mar 29, 2016 · 11:48 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001626971

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.0001 par value^F1,F2,F3	Mar 29, 2016	C	266,310	—	A	984,538	I	By Trust
Common Stock, $0.0001 par value^F1,F2,F3	Mar 29, 2016	C	62,455	—	A	1,046,993	I	By Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F1,F3,F4	—	Mar 29, 2016	C	266,310	D	—	—	Common Stock	266,310	0	I
Series B Preferred Stock^F1,F3,F4	—	Mar 29, 2016	C	62,455	D	—	—	Common Stock	62,455	0	I

F1The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering.
F2A portion of these shares is subject to a right of repurchase held by the Issuer.
F3These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the "Miller-Horning Trust"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller-Horning Trust.
F4The expiration date is not relevant to the conversion of these securities.